[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lower-extremity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lower-extremity":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,55,92,115,149,177,200],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":39,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100596071","negative-pressure-wound-therapy-for-split-thickness-skin-grafting-to-the-lower-leg-after-excision-of-skin-tumour-a-multicentre-randomised-study-100596071",false,"NCT07040683","Negative Pressure Wound Therapy for Split Thickness Skin Grafting to the Lower Leg After Excision of Skin Tumour: A Multicentre Randomised Study","Negative Pressure Wound Therapy for Split Thickness Skin Grafting to the Lower Leg After Excision of Skin Tumour: The Legs Trial - A Multicentre Randomised Study","LEGS","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Undergoing excision of a skin tumour on the lower leg with planned coverage using split-thickness skin grafting (STSG)\n* Eligible procedures include primary excision, secondary excision, or extended excision performed at the same site as a previous tumour surgery\n* Ability to provide written informed consent\n* Ability to comply with postoperative instructions and follow-up visits\n\nExclusion Criteria:\n\n* Inability to follow postoperative instructions due to cognitive impairment, dementia, or significant language barriers\n* Inability to provide informed consent\n* Severe systemic illness, including:\n* Ongoing sepsis\n* Advanced heart failure\n* End-stage renal or liver disease\n* Active chemotherapy within the previous three months\n* Ongoing treatment with immunosuppressive medications, including:\n* Systemic corticosteroids (e.g., prednisone \\>20 mg\u002Fday or equivalent)\n* Calcineurin inhibitors (e.g., cyclosporine, tacrolimus)\n* Antimetabolites (e.g., methotrexate, azathioprine, mycophenolate mofetil)\n* mTOR inhibitors (e.g., sirolimus, everolimus)\n* Biologic therapies (e.g., rituximab, TNF inhibitors, IL-6 inhibitors, IL-1, IL-17, IL-23 inhibitors)\n* Targeted molecular therapies (e.g., JAK inhibitors such as tofacitinib, baricitinib)\n* Other immunosuppressive drugs\n* Previous radiation therapy to the surgical site\n* Presence of severe skin disease affecting the planned graft recipient site (e.g., advanced psoriasis)","ALL","18 Years",{"count":20,"type":21},242,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to compare the effect of negative pressure wound therapy (NPWT) versus traditional dressings on the incidence of transplant infection in adult patients undergoing split-thickness skin grafting (STSG) to the lower leg following excision of a skin tumour. The main questions it aims to answer are:\n\nDoes NPWT reduce the incidence of transplant infection within three months after STSG?\n\nDoes NPWT improve secondary outcomes such as graft take, reduce reoperations, complications, and resource use?\n\nResearchers will compare patients treated with NPWT to patients treated with traditional dressings to see if NPWT results in lower infection rates and better clinical outcomes.\n\nParticipants will:\n\nUndergo excision of a skin tumour on the lower leg followed by STSG.\n\nBe randomized to receive either NPWT or traditional dressings applied over the graft.\n\nFollow a structured postoperative care and mobilisation schedule.\n\nAttend follow-up visits at day 5 and day 14 postoperatively and be monitored through medical record review up to three months after surgery.",[27,28,29,30,31,32,33,34,35,36,37,38],"Skin Transplantation","Skin Grafting","Split Thickness Skin Graft","Negative-Pressure Wound Therapy","Postoperative Complications","Surgical Wound Infection","Lower Extremity","Skin Cancer","Skin Tumour","Wound Healing","Bandages","Leg",[27,28,40,30,31,32,33,36,37,38,41,34],"Split Thickness","Skin Neoplasms","RECRUITING","2026-05-27",{"date":45,"type":46},"2026-05-28","ACTUAL",{"date":48,"type":46},"2025-11-01",{"date":50,"type":21},"2030-03-31",{"name":52,"class":53},"Region Skane","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":54},"100635258","bupivacaine-lidocaine-vs-bupivacaine-for-ultrasound-guided-popliteal-sciatic-nerve-block-100635258","NCT07550348","Bupivacaine-Lidocaine vs Bupivacaine for Ultrasound-Guided Popliteal Sciatic Nerve Block","Bupivacaine-Lidocaine Combination Versus Bupivacaine Alone for Ultrasound-Guided Popliteal Sciatic Nerve Block in Elective Lower Extremity Surgery: A Prospective Randomized Double-Blind Trial","PSSNB-BL","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* American Society of Anesthesiologists (ASA) physical status classification I, II, or III\n* Scheduled for elective distal lower extremity surgery (below-knee)\n* Body mass index (BMI) between 18 and 35 kg\u002Fm²\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* Morbid obesity (BMI ≥35 kg\u002Fm²)\n* Known allergy or hypersensitivity to any local anesthetic agent\n* Severe cardiac, hepatic, or renal disease\n* Pre-existing neurological deficits or peripheral neuropathy\n* Use of anticoagulant therapy\n* History of prior surgery or significant scar tissue in the popliteal fossa\n* Pregnancy\n* Chronic opioid use at home","65 Years",{"count":65,"type":21},60,[24],"This prospective, randomized, double-blind clinical trial aims to compare the efficacy of two local anesthetic regimens for ultrasound-guided popliteal sciatic nerve block in adult patients undergoing elective distal lower extremity surgery.\n\nEligible participants (ages 18-65, ASA physical status I-III, BMI 18-35 kg\u002Fm²) will be randomized into two equal groups of 30. Patients in Group BL will receive a combination of 10 mL 2% lidocaine and 10 mL 0.5% bupivacaine, while patients in Group B will receive 20 mL 0.5% bupivacaine alone, administered via ultrasound-guided popliteal sciatic nerve block prior to surgery.\n\nThe primary outcome is the onset time of sensory and motor blockade. Secondary outcomes include block success rate, duration of sensory and motor block, postoperative opioid consumption, pain scores assessed by the Numeric Rating Scale (NRS) at 2, 4, 8, 12, and 24 hours postoperatively, Quality of Recovery-15 (QoR-15) score, and incidence of rebound pain.\n\nThe study is conducted at Ataturk University Research Hospital, Department of Anesthesiology and Reanimation, Erzurum, Turkey.",[33,69,70,71],"Nerve Block","Pain, Postoperative","Pain, Nerve",[73,74,75,76,77,78,79,80,81,82],"Popliteal sciatic nerve block","Bupivacaine","Lidocaine","Local anesthetic","Ultrasound-guided nerve block","Regional anesthesia","Postoperative analgesia","Block onset time","Lower extremity surgery","QoR-15","2026-05-08",{"date":85,"type":46},"2026-05-12",{"date":87,"type":46},"2025-12-01",{"date":89,"type":21},"2027-03-01",{"name":91,"class":53},"Ataturk University",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":99,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":54},"100560605","photoacoustic-tomography-in-assessment-of-lower-extremity-artery-disease-100560605","NCT06579326","Photoacoustic Tomography in Assessment of Lower Extremity Artery Disease","Multistructural Quantitative Photoacoustic Imaging of Human Feet With Lower Extremity Artery Disease","Inclusion Criteria:\n\n1. Inclusion of the case group 1) LEAD patients; 2) Patients voluntarily take part in the study and write informed consent.\n2. Inclusion of the control group 1) Patients without LEAD by ultrasound and clinical diagnosis; 2) Patients voluntarily take part in the study and write informed consent.\n\nExclusion Criteria:\n\n1. age \\\u003C18 years;\n2. pregnant women, nursing mothers and pregnant women in preparation;\n3. with laser operation contraindication (for example, received a photodynamic therapy in the last month);\n4. with metal implants in lower legs or feet;\n5. with a history of mental illnesses or abuse of drug and alcohol;\n\n7\\) with blood phobia or pathological hypotension; 8) with cerebral hemorrhage or peripheral vascular bleeding risk, or history of stroke; 9) with wounds in lower legs or feet; 10) unable or uncooperative with the experimenter.",true,{"count":101,"type":21},200,"OBSERVATIONAL","Lower extremity artery disease (LEAD) is characterized by low awareness rate and high missed diagnosis rate, leading to low treatment rate and high disabling mortality rate. However, none of the current examination methods can comprehensively and thoroughly evaluate the vascular structure and blood oxygen status of the lower extremity at the same time. Photoacoustic imaging can display millimeter-scale microvessels without the need for contrast agents. The investigators developed photoacoustic tomography (PACT) technology, which wass able to provide three-dimensional and high-resolution photoacoustic images of the target area.The investigators plan to recruit LEAD patients in different disease conditions and healthy volunteers to receive the PACT examination on the feet using this imaging system, and to evaluate the potential clinical role of the imaging system in LEAD, and its added value to current imaging methods.",[33,105],"Photoacoustic","2026-05-05",{"date":108,"type":46},"2026-05-06",{"date":110,"type":46},"2024-11-01",{"date":112,"type":21},"2028-12-31",{"name":114,"class":53},"Sun Yat-sen University",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":148},"100601928","matrion-decellularized-placental-membrane-versus-conventional-wound-management-in-subjects-with-diabetic-foot-ulcers-100601928","NCT07116876","Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers","An Open-Label Trial to Assess the Clinical Effectiveness of Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers","Inclusion Criteria:\n\nTo be considered eligible to participate in this study, a subject must meet the inclusion criteria listed below:\n\n1. Be male or female and aged between 21 and 80 years at the time of informed consent\n2. Have a diagnosis of Type I or Type II diabetes as defined by the American Diabetes Association and have been on a stable anti-diabetic treatment regimen for at least 30 days before the baseline visit.\n3. Have full-thickness wound of the lower extremity, below the ankle\n4. Have a single target ulcer\n5. Have a wound with an area greater than or equal to 1cm2 and less than 25 cm2 with a depth less than or equal to 9 mm\n6. Have a diabetic foot ulcer that has been present for at least 30 days with a Wagner Classification Grade 1 or 2:\n\n   * Grade 1: superficial diabetic ulcer involving the full skin thickness but not underlying tissues\n   * Grade 2: ulcer extension involving ligament, tendon, joint capsule, or fascia, without presence of abscess or osteomyelitis\n7. Have an absence of infection based on Infectious Disease Society of America criteria (assessed at BOTH Screening\u002FVisit 1 and Baseline\u002FVisit 2)\n8. Have an adequate circulation to the affected lower extremity, defined as at least one of the criteria within the previous 60 days:\n\n   * Transcutaneous oxygen measurement at the dorsum of the foot greater or equal to 30 mm Hg\n   * Ankle-brachial index (ABI) ranging from 0.8 to 1.2\n   * At least biphasic Doppler arterial waveforms at the dorsalis pedis and posterior tibial arteries\n9. Have the ability to comply with off-loading and dressing change requirements\n10. Have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (ICF) approved by an institutional review board (IRB), and agree to abide by the study restrictions and return to the site for the required assessments\n11. Have provided written authorization for use and disclosure of protected health information\n12. Have a life expectancy of greater than 6 months\n\nExclusion Criteria:\n\nTo be eligible for entry into the study, the subject must not meet any of the exclusion criteria listed below:\n\n1. Be pregnant or lactating\n2. Subjects with a target wound \\\u003C30 days old at Screening whose wound area has decreased in size ≥50% between the Screening and Baseline Visits (assessed at Baseline\u002FVisit 2)\n3. Have a circulating hemoglobin A1c exceeding 12% within 90 days of the Screening Visit (assessed at Screening\u002FVisit 1 for subjects with labs collected \\\u003C30 days of screening; assessed at Baseline\u002FVisit 2 for subjects with labs collected at screening)\n4. Have a serum creatinine concentration of 3.0 mg\u002FdL or greater within 30 days prior to screening (assessed at Screening\u002FVisit 1 for subjects with labs collected \\\u003C30 days of screening; assessed at Baseline\u002FVisit 2 for subjects with labs collected at screening)\n5. Have a sensitivity to either of the following antibiotics: lincomycin, gentamicin, polymyxin B, or vancomycin\n6. Have a sensitivity to polysorbate 20, N-lauroyl sarcosinate, benzonase or glycerol\n7. Have the wound treated with biomedical or topical growth factors within the previous 30 days before the Screening Visit\n8. Need for any additional concomitant dressing material other than the ones approved for this study\n9. Have clinical signs of an infection at the study ulcer site (assessed at BOTH Screening\u002FVisit 1 and Baseline\u002FVisit 2)\n10. Have the inability to tolerate an off-loading boot\n11. Have a known or suspected disease of the immune system\n12. Have an active or untreated malignancy or active, uncontrolled connective tissue disease\n13. Had a treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids less than 30 days before the Baseline Visit\n14. Have presence of necrosis, purulence, or sinus tracts that cannot be removed by debridement (assessed at Baseline\u002FVisit 2)\n15. Has undergone a revascularization procedure aimed at increasing blood flow in the treatment target limb less than 4 weeks before the Baseline Visit\n16. Have serum aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase levels greater than three times the normal upper limit within 30 days prior to screening (assessed at Screening\u002FVisit 1 if subject had labs collected \\\u003C30 days of screening; assessed at Baseline\u002FVisit 2 if subject had labs collected at screening)\n17. Have active Charcot disease\n18. Have undergone treatment with a living skin equivalent within the last 4 weeks before screening\n19. Have ongoing evidence of peripheral vascular disease, including greater than one nonpalpable pulse on either foot\n20. Have the presence of any condition that in the opinion of the investigator places the subject at undue risk or potentially jeopardizes the quality of the data to be generated","21 Years","80 Years",{"count":125,"type":21},120,[24],"This study will evaluate Matrion™ (LifeNet Health, Inc., Virginia Beach, VA), a placental membrane product, as a treatment for diabetic foot ulcers compared to conventional wound care. Matrion is derived from donated human birth tissue and includes both the amniotic and chorionic layers, along with the trophoblast layer. It is minimally processed using a proprietary decellularization method and terminally sterilized to ensure the membrane is acellular and sterile, making it suitable for surgical applications.",[129,33],"Diabetic Foot Ulcer (DFU)",[131,132,133,134,135,136,137],"diabetic foot ulcer","placental membrane","lower extremity wound","decellularized placental membrane","foot diseases","foot ulcer","conventional wound management","2025-12-09",{"date":140,"type":46},"2025-12-10",{"date":142,"type":46},"2025-06-26",{"date":144,"type":21},"2026-06",{"name":146,"class":147},"LifeNet Health","INDUSTRY",18,{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":54},"100614228","intrathecal-dexmedetomidine-fentanyl-combination-versus-fentanyl-alone-as-adjuvant-to-bupivacaine-in-spinal-anesthesia-for-above-knee-amputation-in-sarcomas-of-lower-extremity-100614228","NCT07276867","Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia for Above Knee Amputation in Sarcomas of Lower Extremity","Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia for Above Knee Amputation in Sarcomas of Lower Extremity: A Randomized, Comparative Study","Inclusion Criteria:\n\n* Age from 18 to 60 years.\n* Both sexes.\n* American Society of Anesthesiologists (ASA) physical status of II-III.\n* Height between 150-185 cm.\n* Body mass index between 18-35 kg\u002Fm².\n* Scheduled for above-knee amputation due to lower limb sarcomas.\n\nExclusion Criteria:\n\n* Allergy to any of the investigated drugs.\n* History of heart block, arrhythmia, or ongoing therapy with beta- or calcium channel- blockers, or angiotensin-converting-enzyme inhibitors.\n* Contraindications to spinal anesthesia.\n* Pregnancy or lactation.\n* Presence of psychiatric illness or chronic pain conditions.","60 Years",{"count":158,"type":21},58,[24],"The current work evaluated whether the combination of intrathecal dexmedetomidine and fentanyl provides superior postoperative analgesia to fentanyl alone when administered with hyperbaric bupivacaine.",[162,163,164,74,165,166,167,33],"Intrathecal","Dexmedetomidine","Fentanyl","Spinal Anesthesia","Above Knee Amputation","Sarcomas","2025-11-30",{"date":170,"type":46},"2025-12-11",{"date":172,"type":46},"2025-10-20",{"date":174,"type":21},"2026-04-01",{"name":176,"class":53},"National Cancer Institute, Egypt",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":184,"targetDuration":186,"studyType":102,"phases":4,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":199},"100411672","c-brace-prospective-registry-100411672","NCT04640584","C-Brace Prospective Registry","A Prospective Registry of Patients Fitted With a Microprocessor-controlled Knee Ankle Foot Orthosis","Inclusion Criteria:\n\n* Patient has been evaluated and successfully tested with the Trial Tool, and has been casted for a C-Brace.\n* Patient is able to communicate, provide feedback, understand and follow instructions during the course of the registry.\n* Patient is willing to provide informed consent.\n\nExclusion Criteria:\n\n* Patient is geographically inaccessible to comply and participate in the registry.\n* Patient has not been casted for a C-Brace fitting.",{"count":185,"type":21},250,"12 Months","To gather prospective safety and effectiveness data for the C-Brace System following the standard of care.",[189,33],"Pareses","2025-04-25",{"date":192,"type":46},"2025-04-30",{"date":194,"type":46},"2015-04",{"date":196,"type":21},"2026-04",{"name":198,"class":147},"Otto Bock Healthcare Products GmbH",76,{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":99,"sex":17,"minAge":18,"maxAge":207,"enrollmentInfo":208,"targetDuration":210,"studyType":102,"phases":4,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":215,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":54},"100581378","foot-biomechanics-and-lower-extremity-muscle-mechanics-100581378","NCT06849531","Foot Biomechanics and Lower Extremity Muscle Mechanics","Evaluation of the Relationship Between Foot Biomechanics and Lower Extremity Muscle Mechanics, Strength and Balance","Inclusion Criteria:\n\n* Willing to participate in the study\n* Aged between 18 and 25 years\n* No regular exercise habits\n\nExclusion Criteria:\n\n* Having a physical disability that prevents participation in the study (e.g., use of a wheelchair, walker, and\u002For crutches, etc.)\n* Having conditions that directly affect balance, such as vertigo or multiple sclerosis (MS)\n* Having a neurological disorder","25 Years",{"count":209,"type":21},56,"1 Day","This study is designed to investigate the relationship between foot biomechanics, balance, lower extremity muscle mechanical properties, and vertical jump in young adults. The aim is to highlight the correlations between foot biomechanics and the other parameters, as well as potential outcomes (if any).",[213,33,214],"Balance","Foot","NOT_YET_RECRUITING","2025-03-02",{"date":218,"type":46},"2025-03-04",{"date":220,"type":21},"2025-03-13",{"date":222,"type":21},"2025-06-06",{"name":224,"class":53},"Bandırma Onyedi Eylül University"]